Compare CLMT & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLMT | SIGA |
|---|---|---|
| Founded | 1916 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 223.8M |
| IPO Year | 2024 | 2016 |
| Metric | CLMT | SIGA |
|---|---|---|
| Price | $52.95 | $3.36 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $28.65 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 650.5K |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 13.24% |
| EPS Growth | ★ 85.39 | N/A |
| EPS | N/A | ★ 0.13 |
| Revenue | ★ $4,137,100,000.00 | N/A |
| Revenue This Year | $3.94 | N/A |
| Revenue Next Year | $1.07 | $224.81 |
| P/E Ratio | ★ N/A | $26.62 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.42 | $2.83 |
| 52 Week High | $59.87 | $9.29 |
| Indicator | CLMT | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 49.36 | 57.33 |
| Support Level | $39.44 | $2.92 |
| Resistance Level | $59.87 | $4.84 |
| Average True Range (ATR) | 2.46 | 0.15 |
| MACD | -0.93 | 0.04 |
| Stochastic Oscillator | 18.98 | 72.65 |
Calumet Inc is a producer of specialty products, including base oils, specialty oils, solvents, esters, and waxes, as well as a variety of fuel and fuel-related products, including asphalt and heavy fuel oils. The company manufactures, formulates, and markets a variety of specialty branded products to customers in various consumer-facing and industrial markets. Its segments include: Specialty Products and Solutions; Montana/Renewables; Performance Brands; and Corporate. The company generates maximum revenue from Fuels, asphalt and other by-products.
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.